Analytical and Chemical Enhancements to Improve Efficacy and Accuracy of Therapeutic Oligonucleotides
See how top pharma players are addressing impure, unstable, and off-target oligos
Boosting the Efficacy of Safe, Scalable, & Precise Vaccines
Innovations in mRNA Technology, RNA Therapeutics, and Cancer Immunotherapy for 2024
.png)
Tumbler: A Highly Customizable Antibody Optimization Suite
On-demand presentation, presented by Michali Izhaky, Bioinformatics Scientist at Charles River
Leading Innovations in Fab, ScFv, & VHH Production and Engineering
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy
On-demand webinar presented by Ritwika Biswas, Field Application Scientist at Sino Biological
Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Biomarkers & Precision Medicine
Enabling Ultrasensitive Protein Quantification with the Quanterix Homebrew Kit
Unique Homebrew Kits give researchers the flexibility to develop custom Simoa assays.
Cell Line Development
Experience the Next Generation in Clonality
Explore the future of single cell seeding.
3D Cell Culture
Using Cancer Organoids to Discover New Therapeutic Targets
The lack of predictive models is a highly limiting factor in the efficacy of projects designed to find new therapeutic targets. Cutting-edge organoid models may be the key to overcoming these challenges and could improve the prediction candidate drug molecules' clinical success.
Antibody & Protein Engineering
Roche Fail to Follow in Eisai’s Footsteps: Alzheimer’s Drug Flunks Phase III Trials
Roche revealed that they will stop all Alzheimer’s trials after anti-amyloid beta antibody gantenerumab fails Phase III trials.
Drug Discovery & Development
Viral Immunotherapy: A New Approach Towards Tackling Solid Tumours
As an alternative avenue for addressing difficult-to-treat cancers, viral immunotherapies hold significant promise. CAN-2409 is well-tolerated in phase II clinical trials in patients with prostate cancer, and new applications may be on the horizon.
Antibody & Protein Engineering
Heart-to-Heart or Head-to-Head: Amgen Heart Drug to Challenge Novartis
New data released from Amgen’s phase II study of olpasiran suggests that the drug could fill a niche in the cardiovascular market.
Universal Vaccines & Vaccine Therapeutics
Mark Doherty, Senior Medical Manager at GSK, leads a Discussion Group on leveraging the mechanisms of action in therapeutic vaccine development.
Tumour Microenvironment
Expert Opinions on Targeting the Tumour Microenvironment: Present Challenges and Future Outlook
The tumour microenvironment is a critical target to immuno-oncologists. Our discussion group brings together authorities in targeting the TME.
Antibody & Protein Engineering
AbbVie Ditch Phase II Autoimmune Drug
AbbVie announced that they are dropping the ROR? inverse agonist, marking the end of their collaboration with Inventiva
Manufacturing & Bioprocessing
Overcoming the Challenges in Cell Therapy Manufacturing
Udayanath Aich, Director at Bristol Myers Squibb, leads a Discussion Group on leveraging advanced technologies and biologics to mitigate challenges.
NextGen Therapeutics
Exploring & Developing Various Biotherapeutic Modalities
Galahad Deperalta, Senior Scientist and Innovation Group Leader at Genentech, leads a Discussion Group on the next generation of biotherapeutic development.
Manufacturing & Bioprocessing
Looking into the Crystal Ball: The Future of Disruptive Cell and Gene Therapy Manufacturing
What will the future hold for autologous cell and gene therapy manufacturing? Tigen Pharma SA, share their predictions on the prospect of disruptive innovation for the industry.